ATXI
Avenue Therapeutics, Inc.
Price Chart
Latest Quote
$0.27
-0.05 (-15.62%)
Current Price
| Previous Close | $0.32 |
| Open | $0.32 |
| Day High | $0.32 |
| Day Low | $0.32 |
| Volume | 600 |
Stock Information
| Shares Outstanding | 3.29M |
| Cash Equivalents | $2.42M |
| Revenue | $1.40M |
| Net Income | $-1.75M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $890K |
| EPS (TTM) | $-0.52 |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-1.53M |
| Sales | $1.40M |
| Income | $-1.75M |
| Book/sh | $0.36 |
| Cash/sh | $0.73 |
| Employees | 1 |
Financial Ratios
| Quick Ratio | 1.90 |
| Current Ratio | 1.94 |
Returns & Margins
| ROA | -43.20% |
| ROE | -101.08% |
| Gross Margin | 100.00% |
| Operating Margin | -149.22% |
| Profit Margin | -124.79% |
Ownership
| Insider Ownership | 13.51% |
| Institutional Ownership | 7.02% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.09 |
| P/S | 0.63 |
| P/B | 0.74 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.32 |
| SMA50 | $0.42 |
| SMA200 | $0.53 |
| RSI | 36.80 |
| ATR | 0.0480 |
| Shares Float | 2.85M |
| Short Float | 2.83% |
| Short Ratio | 0.65 |
| Volatility | -0.17 |
| Rel Volume | 0.55 |
Performance History
| Week | -25.00% |
| Month | -10.00% |
| Quarter | +75.90% |
| 6 Months | -58.48% |
| YTD | -60.64% |
| Year | +29.71% |
| 3 Years | -99.69% |
| 5 Years | -99.99% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-16 | $0.27 | 913 |
| 2026-06-15 | $0.32 | 1,366 |
| 2026-06-12 | $0.32 | 979 |
| 2026-06-11 | $0.30 | 1,121 |
| 2026-06-10 | $0.36 | 0 |
| 2026-06-09 | $0.36 | 4,884 |
| 2026-06-08 | $0.31 | 136 |
| 2026-06-05 | $0.35 | 1,601 |
| 2026-06-04 | $0.35 | 1,732 |
| 2026-06-03 | $0.35 | 3,692 |
| 2026-06-02 | $0.30 | 324 |
| 2026-06-01 | $0.28 | 933 |
| 2026-05-29 | $0.30 | 2,340 |
| 2026-05-28 | $0.29 | 2,966 |
| 2026-05-27 | $0.38 | 401 |
| 2026-05-26 | $0.38 | 1,572 |
| 2026-05-22 | $0.24 | 3,235 |
| 2026-05-21 | $0.28 | 3,671 |
| 2026-05-20 | $0.28 | 0 |
| 2026-05-19 | $0.28 | 1,513 |
| 2026-05-18 | $0.31 | 679 |
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
đ° Latest News
No news articles available at the moment. Check back later for updates on ATXI.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $332,000 | $1,160,000 | $0 |
| Total Expenses | $11,283,000 | $14,540,000 | $8,043,000 | $3,738,000 |
| Other Income Expense | $-589,000 | $4,258,000 | $5,580,000 | - |
| Net Non Operating Interest Income Expense | $176,000 | $-206,000 | $-1,140,000 | $7,000 |
| Interest Expense Non Operating | $0 | $332,000 | $1,160,000 | $0 |
| Operating Expense | $11,283,000 | $14,540,000 | $8,043,000 | $3,738,000 |
| General And Administrative Expense | $4,638,000 | $4,179,000 | $5,345,000 | $2,484,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,652,000 | $-10,377,000 | $-3,552,000 | $-3,731,000 |
| Net Interest Income | $176,000 | $-206,000 | $-1,140,000 | $7,000 |
| Interest Income | $176,000 | $126,000 | $20,000 | $7,000 |
| Normalized Income | $-11,063,000 | $-14,635,000 | $-9,132,000 | $-3,731,000 |
| Net Income From Continuing And Discontinued Operation | $-11,652,000 | $-10,377,000 | $-3,552,000 | $-3,731,000 |
| Total Operating Income As Reported | $-11,283,000 | $-14,540,000 | $-8,043,000 | $-3,738,000 |
| Net Income Common Stockholders | $-11,652,000 | $-10,377,000 | $-3,552,000 | $-3,731,000 |
| Net Income | $-11,652,000 | $-10,377,000 | $-3,552,000 | $-3,731,000 |
| Net Income Including Noncontrolling Interests | $-11,696,000 | $-10,488,000 | $-3,603,000 | $-3,731,000 |
| Net Income Continuous Operations | $-11,696,000 | $-10,488,000 | $-3,603,000 | $-3,731,000 |
| Pretax Income | $-11,696,000 | $-10,488,000 | $-3,603,000 | $-3,731,000 |
| Interest Income Non Operating | $176,000 | $126,000 | $20,000 | $7,000 |
| Operating Income | $-11,283,000 | $-14,540,000 | $-8,043,000 | $-3,738,000 |
| Per Share | ||||
| Diluted EPS | $-15.79 | $-73.48 | $-122.25 | $-246.75 |
| Basic EPS | $-15.79 | $-73.48 | $-122.25 | $-246.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,107,000 | $-14,414,000 | $-8,023,000 | $-3,731,000 |
| Total Unusual Items | $-589,000 | $4,258,000 | $5,580,000 | - |
| Total Unusual Items Excluding Goodwill | $-589,000 | $4,258,000 | $5,580,000 | - |
| EBITDA (Bullshit earnings) | $-11,696,000 | $-10,156,000 | $-2,443,000 | $-3,731,000 |
| EBIT | $-11,696,000 | $-10,156,000 | $-2,443,000 | $-3,731,000 |
| Diluted Average Shares | $1,295,207 | $141,222 | $29,135 | $15,108 |
| Basic Average Shares | $1,295,207 | $141,222 | $29,135 | $15,108 |
| Diluted NI Availto Com Stockholders | $-11,652,000 | $-10,377,000 | $-3,552,000 | $-3,731,000 |
| Minority Interests | $44,000 | $111,000 | $51,000 | $0 |
| Gain On Sale Of Security | $-589,000 | $4,258,000 | $5,580,000 | - |
| Research And Development | $6,645,000 | $10,361,000 | $2,698,000 | $1,254,000 |
| Selling General And Administration | $4,638,000 | $4,179,000 | $5,345,000 | $2,484,000 |
| Other Gand A | $4,638,000 | $4,179,000 | $5,345,000 | $2,484,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,797,000 | $1,582,000 | $3,905,000 | $3,451,000 |
| Total Assets | $2,672,000 | $1,850,000 | $6,845,000 | $3,960,000 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $2,672,000 | $1,850,000 | $6,845,000 | $3,960,000 |
| Other Current Assets | $78,000 | $67,000 | $137,000 | $107,000 |
| Cash Cash Equivalents And Short Term Investments | $2,594,000 | $1,783,000 | $6,708,000 | $3,763,000 |
| Cash And Cash Equivalents | $2,594,000 | $1,783,000 | $6,708,000 | $3,763,000 |
| Receivables | - | - | $0 | $90,000 |
| Prepaid Assets | - | - | - | $107,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $816,000 | $1,196,000 | $3,579,000 | $509,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $816,000 | $1,196,000 | $3,579,000 | $509,000 |
| Other Current Liabilities | $16,000 | $586,000 | $2,609,000 | - |
| Payables And Accrued Expenses | $782,000 | $599,000 | $771,000 | $485,000 |
| Payables | $301,000 | $401,000 | $150,000 | $362,000 |
| Accounts Payable | $155,000 | $78,000 | $129,000 | $304,000 |
| Equity | ||||
| Common Stock Equity | $2,797,000 | $1,582,000 | $3,905,000 | $3,451,000 |
| Total Equity Gross Minority Interest | $1,856,000 | $654,000 | $3,266,000 | $3,451,000 |
| Stockholders Equity | $2,797,000 | $1,582,000 | $3,905,000 | $3,451,000 |
| Retained Earnings | $-102,580,000 | $-90,928,000 | $-80,551,000 | $-76,999,000 |
| Other | ||||
| Ordinary Shares Number | $2,108,670 | $341,301 | $63,651 | $18,746 |
| Share Issued | $2,108,670 | $341,301 | $63,651 | $18,746 |
| Tangible Book Value | $2,797,000 | $1,582,000 | $3,905,000 | $3,451,000 |
| Invested Capital | $2,797,000 | $1,582,000 | $3,905,000 | $3,451,000 |
| Working Capital | $1,856,000 | $654,000 | $3,266,000 | $3,451,000 |
| Total Capitalization | $2,797,000 | $1,582,000 | $3,905,000 | $3,451,000 |
| Minority Interest | $-941,000 | $-928,000 | $-639,000 | $0 |
| Additional Paid In Capital | $105,377,000 | $92,507,000 | $84,456,000 | $80,450,000 |
| Capital Stock | $0 | $3,000 | $0 | $0 |
| Common Stock | $0 | $3,000 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $18,000 | $11,000 | $199,000 | $24,000 |
| Current Accrued Expenses | $481,000 | $198,000 | $621,000 | $123,000 |
| Dueto Related Parties Current | $146,000 | $323,000 | $21,000 | $58,000 |
| Treasury Shares Number | - | $0 | - | - |
| Duefrom Related Parties Current | - | - | $0 | $90,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-9,026,000 | $-12,451,000 | $-7,596,000 | $-3,750,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,026,000 | $-9,451,000 | $-7,596,000 | $-3,750,000 |
| Cash Flow From Continuing Operating Activities | $-9,026,000 | $-9,451,000 | $-7,596,000 | $-3,750,000 |
| Operating Gains Losses | $589,000 | $-4,258,000 | $-5,580,000 | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-3,000,000 | $0 | $0 |
| Cash Flow From Continuing Investing Activities | $0 | $-3,000,000 | $0 | $0 |
| Capital Expenditure | - | $-3,000,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $1,623,000 | $7,525,000 | $11,497,000 | $5,044,000 |
| Financing Cash Flow | $9,837,000 | $7,526,000 | $10,541,000 | $4,381,000 |
| Cash Flow From Continuing Financing Activities | $9,837,000 | $7,526,000 | $10,541,000 | $4,381,000 |
| Net Other Financing Charges | $-1,207,000 | - | $-508,000 | $-663,000 |
| Net Common Stock Issuance | $1,623,000 | $7,525,000 | $10,393,000 | $5,044,000 |
| Common Stock Issuance | $1,623,000 | $7,525,000 | $11,497,000 | $5,044,000 |
| Repurchase Of Capital Stock | - | $0 | $-1,104,000 | $0 |
| Other | ||||
| End Cash Position | $2,594,000 | $1,783,000 | $6,708,000 | $3,763,000 |
| Beginning Cash Position | $1,783,000 | $6,708,000 | $3,763,000 | $3,132,000 |
| Changes In Cash | $811,000 | $-4,925,000 | $2,945,000 | $631,000 |
| Proceeds From Stock Option Exercised | $9,421,000 | $1,000 | $148,000 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-3,000,000 | $0 | $0 |
| Purchase Of Intangibles | $0 | $-3,000,000 | $0 | $0 |
| Change In Working Capital | $179,000 | $-290,000 | $408,000 | $-461,000 |
| Change In Payables And Accrued Expense | $190,000 | $-360,000 | $348,000 | $-377,000 |
| Change In Prepaid Assets | $-11,000 | $70,000 | $-30,000 | $6,000 |
| Other Non Cash Items | $666,000 | $4,679,000 | $530,000 | - |
| Stock Based Compensation | $1,236,000 | $906,000 | $649,000 | $442,000 |
| Gain Loss On Investment Securities | $589,000 | $-4,258,000 | $-5,580,000 | - |
| Net Income From Continuing Operations | $-11,696,000 | $-10,488,000 | $-3,603,000 | $-3,731,000 |
| Common Stock Payments | - | $0 | $-1,104,000 | $0 |
| Change In Receivables | - | $0 | $90,000 | $-90,000 |
Fetched: 2026-02-02